New perspectives on the treatment of mycobacterial infections using antibiotics

More than 100 years have passed since the discovery of Mycobacterium tuberculosis , in 1882, as the pathogen that causes tuberculosis (TB). However, globally, TB is still one of the leading causes of death by infectious diseases. In 2018, approximately 10.0 million people were diagnosed with TB owin...

Full description

Saved in:
Bibliographic Details
Published inApplied microbiology and biotechnology Vol. 104; no. 10; pp. 4197 - 4209
Main Authors He, Yile, Fan, Aili, Han, Meng, Zhang, Yihan, Tong, Yigang, Zheng, Guojun, Zhu, Shaozhou
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.05.2020
Springer
Springer Nature B.V
Subjects
Antibiotics
Antitubercular agents
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
Bacterial infections
Bioinformatics
Biomedical and Life Sciences
Biotechnology
Care and treatment
Clinical Trials as Topic
Computational Biology
Development strategies
Drug development
Drug discovery
Drug resistance
Drug resistance in microorganisms
Drugs
Health aspects
Homeopathy
Humans
Infectious diseases
Life Sciences
Materia medica and therapeutics
Microbial Genetics and Genomics
Microbiology
Mini-Review
Multidrug resistance
multiple drug resistance
Mycobacterium tuberculosis
Mycobacterium tuberculosis - drug effects
pathogens
Patient compliance
phage therapy
Phages
Pharmaceutical industry
R&D
Research & development
research and development
Sustainable development
synthetic biology
Therapeutics
Tuberculosis
Tuberculosis - drug therapy
Tuberculosis - microbiology
Tuberculosis, Multidrug-Resistant - drug therapy
Lassomycin
Teixobactin
Anti-TB
Natural products
Phage therapy
Synthetic biology
Genome mining
Mycobacterium tuberculosis
Online AccessGet full text

Cover

Abstract More than 100 years have passed since the discovery of Mycobacterium tuberculosis , in 1882, as the pathogen that causes tuberculosis (TB). However, globally, TB is still one of the leading causes of death by infectious diseases. In 2018, approximately 10.0 million people were diagnosed with TB owing to the development of advanced strategies by M. tuberculosis to resist antibiotics, including the development of a dormant state. The World Health Organization (WHO) and the Sustainable Development Goals (SDGs) are dedicated to ending TB by 2030. However, the development of strategies to discover new TB drugs and new therapies is crucial for the achievement of this goal. Unfortunately, the rapid occurrence of multidrug-resistant strains of M. tuberculosis has worsened the current situation, thereby warranting prioritized discovery of new anti-TB drugs and the development of new treatment regimens in academia and the pharmaceutical industry. In this mini review, we provide a brief overview of the current research and development pipeline for new anti-TB drugs and present our perspective of TB drug innovation. The data presented herein may enable the introduction of more effective medicines and therapeutic regimens into the market. Key Points • The Updated Global New TB Drug Pipelines are briefly summarized. • Novel strategies for the discovery of new TB drugs, including novel sources, bioinformatics, and synthetic biology strategies, are discussed. • New therapeutic options, including living therapeutics and phage therapy, are proposed.
AbstractList More than 100 years have passed since the discovery of Mycobacterium tuberculosis, in 1882, as the pathogen that causes tuberculosis (TB). However, globally, TB is still one of the leading causes of death by infectious diseases. In 2018, approximately 10.0 million people were diagnosed with TB owing to the development of advanced strategies by M. tuberculosis to resist antibiotics, including the development of a dormant state. The World Health Organization (WHO) and the Sustainable Development Goals (SDGs) are dedicated to ending TB by 2030. However, the development of strategies to discover new TB drugs and new therapies is crucial for the achievement of this goal. Unfortunately, the rapid occurrence of multidrug-resistant strains of M. tuberculosis has worsened the current situation, thereby warranting prioritized discovery of new anti-TB drugs and the development of new treatment regimens in academia and the pharmaceutical industry. In this mini review, we provide a brief overview of the current research and development pipeline for new anti-TB drugs and present our perspective of TB drug innovation. The data presented herein may enable the introduction of more effective medicines and therapeutic regimens into the market.Key Points• The Updated Global New TB Drug Pipelines are briefly summarized.• Novel strategies for the discovery of new TB drugs, including novel sources, bioinformatics, and synthetic biology strategies, are discussed.• New therapeutic options, including living therapeutics and phage therapy, are proposed.
More than 100 years have passed since the discovery of Mycobacterium tuberculosis, in 1882, as the pathogen that causes tuberculosis (TB). However, globally, TB is still one of the leading causes of death by infectious diseases. In 2018, approximately 10.0 million people were diagnosed with TB owing to the development of advanced strategies by M. tuberculosis to resist antibiotics, including the development of a dormant state. The World Health Organization (WHO) and the Sustainable Development Goals (SDGs) are dedicated to ending TB by 2030. However, the development of strategies to discover new TB drugs and new therapies is crucial for the achievement of this goal. Unfortunately, the rapid occurrence of multidrug-resistant strains of M. tuberculosis has worsened the current situation, thereby warranting prioritized discovery of new anti-TB drugs and the development of new treatment regimens in academia and the pharmaceutical industry. In this mini review, we provide a brief overview of the current research and development pipeline for new anti-TB drugs and present our perspective of TB drug innovation. The data presented herein may enable the introduction of more effective medicines and therapeutic regimens into the market.Key Points• The Updated Global New TB Drug Pipelines are briefly summarized.• Novel strategies for the discovery of new TB drugs, including novel sources, bioinformatics, and synthetic biology strategies, are discussed.• New therapeutic options, including living therapeutics and phage therapy, are proposed.More than 100 years have passed since the discovery of Mycobacterium tuberculosis, in 1882, as the pathogen that causes tuberculosis (TB). However, globally, TB is still one of the leading causes of death by infectious diseases. In 2018, approximately 10.0 million people were diagnosed with TB owing to the development of advanced strategies by M. tuberculosis to resist antibiotics, including the development of a dormant state. The World Health Organization (WHO) and the Sustainable Development Goals (SDGs) are dedicated to ending TB by 2030. However, the development of strategies to discover new TB drugs and new therapies is crucial for the achievement of this goal. Unfortunately, the rapid occurrence of multidrug-resistant strains of M. tuberculosis has worsened the current situation, thereby warranting prioritized discovery of new anti-TB drugs and the development of new treatment regimens in academia and the pharmaceutical industry. In this mini review, we provide a brief overview of the current research and development pipeline for new anti-TB drugs and present our perspective of TB drug innovation. The data presented herein may enable the introduction of more effective medicines and therapeutic regimens into the market.Key Points• The Updated Global New TB Drug Pipelines are briefly summarized.• Novel strategies for the discovery of new TB drugs, including novel sources, bioinformatics, and synthetic biology strategies, are discussed.• New therapeutic options, including living therapeutics and phage therapy, are proposed.
More than 100 years have passed since the discovery of Mycobacterium tuberculosis, in 1882, as the pathogen that causes tuberculosis (TB). However, globally, TB is still one of the leading causes of death by infectious diseases. In 2018, approximately 10.0 million people were diagnosed with TB owing to the development of advanced strategies by M. tuberculosis to resist antibiotics, including the development of a dormant state. The World Health Organization (WHO) and the Sustainable Development Goals (SDGs) are dedicated to ending TB by 2030. However, the development of strategies to discover new TB drugs and new therapies is crucial for the achievement of this goal. Unfortunately, the rapid occurrence of multidrug-resistant strains of M. tuberculosis has worsened the current situation, thereby warranting prioritized discovery of new anti-TB drugs and the development of new treatment regimens in academia and the pharmaceutical industry. In this mini review, we provide a brief overview of the current research and development pipeline for new anti-TB drugs and present our perspective of TB drug innovation. The data presented herein may enable the introduction of more effective medicines and therapeutic regimens into the market.Key Points• The Updated Global New TB Drug Pipelines are briefly summarized.• Novel strategies for the discovery of new TB drugs, including novel sources, bioinformatics, and synthetic biology strategies, are discussed.• New therapeutic options, including living therapeutics and phage therapy, are proposed.
More than 100 years have passed since the discovery of Mycobacterium tuberculosis, in 1882, as the pathogen that causes tuberculosis (TB). However, globally, TB is still one of the leading causes of death by infectious diseases. In 2018, approximately 10.0 million people were diagnosed with TB owing to the development of advanced strategies by M. tuberculosis to resist antibiotics, including the development of a dormant state. The World Health Organization (WHO) and the Sustainable Development Goals (SDGs) are dedicated to ending TB by 2030. However, the development of strategies to discover new TB drugs and new therapies is crucial for the achievement of this goal. Unfortunately, the rapid occurrence of multidrug-resistant strains of M. tuberculosis has worsened the current situation, thereby warranting prioritized discovery of new anti-TB drugs and the development of new treatment regimens in academia and the pharmaceutical industry. In this mini review, we provide a brief overview of the current research and development pipeline for new anti-TB drugs and present our perspective of TB drug innovation. The data presented herein may enable the introduction of more effective medicines and therapeutic regimens into the market.Key Points
More than 100 years have passed since the discovery of Mycobacterium tuberculosis , in 1882, as the pathogen that causes tuberculosis (TB). However, globally, TB is still one of the leading causes of death by infectious diseases. In 2018, approximately 10.0 million people were diagnosed with TB owing to the development of advanced strategies by M. tuberculosis to resist antibiotics, including the development of a dormant state. The World Health Organization (WHO) and the Sustainable Development Goals (SDGs) are dedicated to ending TB by 2030. However, the development of strategies to discover new TB drugs and new therapies is crucial for the achievement of this goal. Unfortunately, the rapid occurrence of multidrug-resistant strains of M. tuberculosis has worsened the current situation, thereby warranting prioritized discovery of new anti-TB drugs and the development of new treatment regimens in academia and the pharmaceutical industry. In this mini review, we provide a brief overview of the current research and development pipeline for new anti-TB drugs and present our perspective of TB drug innovation. The data presented herein may enable the introduction of more effective medicines and therapeutic regimens into the market. Key Points • The Updated Global New TB Drug Pipelines are briefly summarized. • Novel strategies for the discovery of new TB drugs, including novel sources, bioinformatics, and synthetic biology strategies, are discussed. • New therapeutic options, including living therapeutics and phage therapy, are proposed.
Audience Academic
Author Fan, Aili
Han, Meng
Zhu, Shaozhou
Zhang, Yihan
Zheng, Guojun
He, Yile
Tong, Yigang
Author_xml – sequence: 1
  givenname: Yile
  surname: He
  fullname: He, Yile
  organization: State Key Laboratory of Chemical Resources Engineering, Beijing University of Chemical Technology, College of Life Science and Technology, Beijing University of Chemical Technology
– sequence: 2
  givenname: Aili
  surname: Fan
  fullname: Fan, Aili
  organization: College of Life Science and Technology, Beijing University of Chemical Technology
– sequence: 3
  givenname: Meng
  surname: Han
  fullname: Han, Meng
  organization: MOE Key Laboratory of Bioinformatics, School of Life Sciences, Tsinghua University
– sequence: 4
  givenname: Yihan
  surname: Zhang
  fullname: Zhang, Yihan
  organization: State Key Laboratory of Chemical Resources Engineering, Beijing University of Chemical Technology, College of Life Science and Technology, Beijing University of Chemical Technology
– sequence: 5
  givenname: Yigang
  surname: Tong
  fullname: Tong, Yigang
  organization: State Key Laboratory of Chemical Resources Engineering, Beijing University of Chemical Technology, College of Life Science and Technology, Beijing University of Chemical Technology
– sequence: 6
  givenname: Guojun
  orcidid: 0000-0001-9204-2694
  surname: Zheng
  fullname: Zheng, Guojun
  email: zhenggj@mail.buct.edu.cn
  organization: State Key Laboratory of Chemical Resources Engineering, Beijing University of Chemical Technology, College of Life Science and Technology, Beijing University of Chemical Technology
– sequence: 7
  givenname: Shaozhou
  orcidid: 0000-0003-3106-4085
  surname: Zhu
  fullname: Zhu, Shaozhou
  email: zhusz@mail.buct.edu.cn
  organization: State Key Laboratory of Chemical Resources Engineering, Beijing University of Chemical Technology, College of Life Science and Technology, Beijing University of Chemical Technology
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32185432$$D View this record in MEDLINE/PubMed
BookMark eNqFkktv1DAUhS1URKeFP8ACRWIDixQ_YjteVhWFShWVeKwtx7kZXCX2YDuF_vs6TKtqKjTIC0v2d66P7z1H6MAHDwi9JviEYCw_JIwpZzWmuCaYE1bTZ2hFGkZrLEhzgFaYSF5LrtpDdJTSNcaEtkK8QIeMkpYXcIWuvsDvagMxbcBmdwOpCr7KP6HKEUyewOcqDNV0a0NnbIbozFg5Pyxw8Kmak_PryvjsOheys-klej6YMcGr-_0Y_Tj_-P3sc3159eni7PSytlw2uaamB0MNZZzQgbdSdRwMNgNpZc-ZIqQXjHVNuVKdEsRKzIw0pOuZZVjgjh2jd9u6mxh-zZCynlyyMI7GQ5iTpg1TDSOkpf9HmWxbJbnkBX37BL0Oc_TlI5oRxRllROylKFMCq1YK9UitzQi69CzkaOzytD4VlDaYS7GYO_kHVVYPk7Nl3oMr5zuC9zuCwmT4k9dmTklffPu6y765Nzp3E_R6E91k4q1-GH8B2i1gY0gpwqCty2YZbXHhRk2wXpKmt0nTJWn6b9L0IqVPpA_V94rYVpQK7NcQHzu3R3UHkyjgIw
CitedBy_id crossref_primary_10_1016_j_molstruc_2023_135319
crossref_primary_10_1021_acs_jcim_2c00531
crossref_primary_10_1016_j_bioorg_2024_107138
crossref_primary_10_15252_embr_202256033
crossref_primary_10_1016_j_sciaf_2020_e00522
crossref_primary_10_3390_pathogens9070522
crossref_primary_10_1002_adtp_202400249
crossref_primary_10_1039_D4RA02746A
crossref_primary_10_3390_cells10123476
crossref_primary_10_1093_femsre_fuaa032
crossref_primary_10_1016_j_heliyon_2025_e42674
Cites_doi 10.1074/jbc.M117.794099
10.1016/j.addr.2016.04.026
10.1021/cr030112j
10.1007/s10295-019-02197-z
10.1016/S0140-6736(14)62002-X
10.1002/chem.201704167
10.1002/anie.200906114
10.1016/j.cell.2019.09.015
10.1038/nm1306
10.1038/nbt.3879
10.1016/S1473-3099(18)30513-9
10.1038/s41579-018-0141-x
10.1021/acssynbio.8b00457
10.1016/j.chembiol.2014.01.014
10.1093/jac/dkr444
10.1186/1471-2164-15-983
10.1128/AAC.45.7.1943-1946.2001
10.1016/j.drudis.2016.09.014
10.1007/s00253-019-09645-x
10.1021/acs.accounts.5b00156
10.1016/S1473-3099(18)30110-5
10.1016/j.mib.2007.08.001
10.1021/ja056780z
10.1016/j.copbio.2018.01.028
10.1007/s12088-014-0498-0
10.1016/S2213-2600(15)00063-6
10.1074/jbc.M113.492173
10.1016/j.mib.2007.05.005
10.1007/s00253-019-09771-6
10.1056/Nejmoa1313865
10.1016/S0140-6736(10)60483-7
10.1002/1439-7633(20020301)3:2/3<124::aid-cbic124>3.0.co;2-j
10.1016/j.cmi.2016.10.022
10.1038/nature18634
10.1038/srep30375
10.1016/j.tube.2014.04.001
10.1093/jac/dkv054
10.1021/acs.joc.7b02462
10.1093/nar/gkv437
10.1016/S2213-2600(18)30057-2
10.1056/NEJMoa1112433
10.1016/j.copbio.2015.05.004
10.1007/s00253-012-3973-8
10.1039/C4CC07778D
10.1007/s40265-014-0241-5
10.1016/j.vetpar.2013.04.004
10.1038/nature09657
10.1016/j.cell.2015.11.031
10.1038/nrmicro.2017.172
10.1038/s41586-019-1791-1
10.1016/j.copbio.2010.03.011
10.1016/S1473-3099(02)00292-X
10.1128/aac.02877-15
10.1016/S0140-6736(06)68392-X
10.1128/aac.05708-11
10.1093/jac/dkv175
10.1016/j.coph.2013.07.002
10.1016/S0140-6736(06)68384-0
10.1016/j.cbpa.2010.10.027
10.2174/1389201019666180731120544
10.1016/S1473-3099(04)01109-0
10.1002/anie.201807970
10.1056/NEJMra1413919
10.1007/s00253-018-9193-0
10.1128/aac.01326-06
10.1016/S1473-3099(09)70041-6
10.1038/s41467-018-06587-2
10.1073/pnas.0709132105
10.1016/j.tips.2016.05.001
10.1038/msb.2011.55
10.1128/aac.46.11.3484-3489.2002
10.1038/425225a
10.1016/S1473-3099(13)70015-X
10.1016/S1473-3099(16)00070-0
10.1016/j.ijid.2016.12.024
10.1021/sb500090b
10.2165/00003495-199754050-00003
10.1016/j.tim.2015.01.006
10.1038/nature14098
10.1093/emph/eoy005
10.1016/S1369-5274(98)80036-2
10.1016/j.ijantimicag.2017.01.042
10.1016/S1473-3099(13)70328-1
10.1038/s41591-019-0437-z
10.1016/S0140-6736(15)60570-0
10.1007/s40265-019-01207-9
10.1074/jbc.M114.572636
10.1056/NEJMp1314385
10.1007/s00253-012-4285-8
10.1111/nyas.14282
10.1007/978-981-32-9413-4_25
10.1128/CMR.00060-17
ContentType Journal Article
Copyright Springer-Verlag GmbH Germany, part of Springer Nature 2020
COPYRIGHT 2020 Springer
Springer-Verlag GmbH Germany, part of Springer Nature 2020.
Copyright Springer Nature B.V. May 2020
Copyright_xml – notice: Springer-Verlag GmbH Germany, part of Springer Nature 2020
– notice: COPYRIGHT 2020 Springer
– notice: Springer-Verlag GmbH Germany, part of Springer Nature 2020.
– notice: Copyright Springer Nature B.V. May 2020
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
ISR
3V.
7QL
7T7
7WY
7WZ
7X5
7X7
7XB
87Z
88A
88E
88I
8AO
8FD
8FE
8FH
8FI
8FJ
8FK
8FL
ABUWG
AEUYN
AFKRA
AZQEC
BBNVY
BENPR
BEZIV
BHPHI
C1K
CCPQU
DWQXO
FR3
FRNLG
FYUFA
F~G
GHDGH
GNUQQ
HCIFZ
K60
K6~
K9.
L.-
LK8
M0C
M0S
M1P
M2P
M7N
M7P
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQBIZ
PQBZA
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
7S9
L.6
DOI 10.1007/s00253-020-10513-2
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Gale In Context: Science
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Industrial and Applied Microbiology Abstracts (Microbiology A)
ABI/INFORM Collection
ABI/INFORM Global (PDF only)
Entrepreneurship Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ABI/INFORM Global (Alumni Edition)
Biology Database (Alumni Edition)
Medical Database (Alumni Edition)
Science Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ABI/INFORM Collection (Alumni Edition)
ProQuest Central (Alumni Edition)
ProQuest One Sustainability
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Business Premium Collection
Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Business Premium Collection (Alumni)
Health Research Premium Collection
ABI/INFORM Global (Corporate)
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Business Collection (Alumni Edition)
ProQuest Business Collection
ProQuest Health & Medical Complete (Alumni)
ABI/INFORM Professional Advanced
ProQuest Biological Science Collection
ABI/INFORM Global
Health & Medical Collection (Alumni Edition)
Medical Database
Science Database
Algology Mycology and Protozoology Abstracts (Microbiology C)
Biological Science Database
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Business
ProQuest One Business (Alumni)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Business Collection (Alumni Edition)
ProQuest Central Student
ProQuest Central Essentials
SciTech Premium Collection
ProQuest Central China
ABI/INFORM Complete
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest Entrepreneurship
Business Premium Collection
ABI/INFORM Global
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest Business Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ABI/INFORM Global (Corporate)
ProQuest One Business
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Biology Journals (Alumni Edition)
ProQuest Central
ABI/INFORM Professional Advanced
ProQuest Health & Medical Research Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
Algology Mycology and Protozoology Abstracts (Microbiology C)
ABI/INFORM Complete (Alumni Edition)
ABI/INFORM Global (Alumni Edition)
ProQuest Central Basic
ProQuest Science Journals
ProQuest SciTech Collection
ProQuest Medical Library
ProQuest One Business (Alumni)
ProQuest Central (Alumni)
Business Premium Collection (Alumni)
MEDLINE - Academic
AGRICOLA
AGRICOLA - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
ProQuest Business Collection (Alumni Edition)
AGRICOLA



ProQuest Business Collection (Alumni Edition)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Engineering
Biology
EISSN 1432-0614
EndPage 4209
ExternalDocumentID A622405762
32185432
10_1007_s00253_020_10513_2
Genre Journal Article
Review
GrantInformation_xml – fundername: Natural Science Foundation of Beijing Municipality (CN)
  grantid: 7202107
– fundername: National Natural Science Foundation of China
  grantid: 21706005
  funderid: http://dx.doi.org/10.13039/501100001809
– fundername: National Natural Science Foundation of China
  grantid: 21706005
GroupedDBID ---
-4W
-58
-5G
-BR
-EM
-Y2
-~C
.4S
.86
.DC
.VR
06C
06D
0R~
0VY
199
1N0
203
23M
28-
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3SX
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5VS
67N
67Z
6J9
6NX
78A
7WY
7X7
88A
88E
88I
8AO
8CJ
8FE
8FH
8FI
8FJ
8FL
8TC
8UJ
95-
95.
95~
96X
A8Z
AAAVM
AABHQ
AAHBH
AAHNG
AAIAL
AAJKR
AAJSJ
AAKKN
AANXM
AANZL
AARHV
AARTL
AATVU
AAUYE
AAWCG
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDBF
ABDZT
ABECU
ABEEZ
ABFTV
ABHLI
ABHQN
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMOR
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTAH
ABTEG
ABTHY
ABTKH
ABTMW
ABULA
ABUWG
ABWNU
ABXPI
ACACY
ACBXY
ACGFO
ACGFS
ACGOD
ACHSB
ACHXU
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPRK
ACREN
ACUHS
ACULB
ACZOJ
ADBBV
ADHIR
ADIMF
ADINQ
ADKNI
ADKPE
ADRFC
ADTPH
ADURQ
ADYFF
ADYOE
ADYPR
ADZKW
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEUYN
AEVLU
AEXYK
AFBBN
AFEXP
AFFNX
AFGCZ
AFGXO
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFYQB
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHKAY
AHMBA
AHSBF
AHYZX
AI.
AIAKS
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMTXH
AMXSW
AMYLF
AOCGG
ARCSS
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
AZQEC
B-.
B0M
BA0
BBNVY
BBWZM
BDATZ
BENPR
BEZIV
BGNMA
BHPHI
BPHCQ
BVXVI
C24
C6C
CAG
CCPQU
COF
CS3
CSCUP
D1J
DDRTE
DL5
DNIVK
DPUIP
DWQXO
EAD
EAP
EBD
EBLON
EBO
EBS
EDH
EDO
EIOEI
EJD
EMB
EMK
EMOBN
EN4
EPAXT
EPL
ESBYG
ESX
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRNLG
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNUQQ
GNWQR
GQ6
GQ7
GQ8
GROUPED_ABI_INFORM_COMPLETE
GXS
H13
HCIFZ
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I-F
I09
IAG
IAO
IEP
IHE
IHR
IJ-
IKXTQ
INH
INR
ISR
ITM
IWAJR
IXC
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
K60
K6~
KDC
KOV
KOW
KPH
LAS
LK8
LLZTM
M0C
M0L
M1P
M2P
M4Y
M7P
MA-
ML0
MM.
N2Q
NB0
NDZJH
NHB
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P0-
P19
P2P
PF0
PQBIZ
PQBZA
PQQKQ
PROAC
PSQYO
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
RNS
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S3A
S3B
SAP
SBY
SCLPG
SCM
SDH
SDM
SHX
SISQX
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZN
T13
T16
TEORI
TH9
TSG
TSK
TSV
TUC
TUS
U2A
U9L
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
VH1
W23
W48
WH7
WJK
WK6
WK8
YLTOR
Z45
Z5O
Z7R
Z7S
Z7U
Z7V
Z7W
Z7X
Z7Y
Z7Z
Z82
Z83
Z84
Z85
Z86
Z87
Z88
Z8M
Z8N
Z8O
Z8P
Z8Q
Z8R
Z8S
Z8T
Z8V
Z8W
Z8Y
Z8Z
Z91
Z92
ZMTXR
ZOVNA
ZXP
ZY4
~02
~8M
~EX
~KM
AASML
AAYXX
ABDBE
ABFSG
ACSTC
ADHKG
AEZWR
AFHIU
AGQPQ
AHPBZ
AHWEU
AIXLP
AYFIA
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
PJZUB
PPXIY
PQGLB
AEIIB
PMFND
7QL
7T7
7X5
7XB
8FD
8FK
C1K
FR3
K9.
L.-
M7N
P64
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
7S9
L.6
ID FETCH-LOGICAL-c574t-2adea2a23512f5879b5ea0af187d53911d633b4f589b961c703a7a1bd3c3060b3
IEDL.DBID 7X7
ISSN 0175-7598
1432-0614
IngestDate Fri Jul 11 07:09:27 EDT 2025
Tue Aug 05 10:10:24 EDT 2025
Wed Aug 13 06:17:14 EDT 2025
Wed Aug 13 09:27:27 EDT 2025
Tue Jun 17 21:04:39 EDT 2025
Tue Jun 10 20:53:13 EDT 2025
Fri Jun 27 05:04:20 EDT 2025
Mon Jul 21 05:40:55 EDT 2025
Tue Jul 01 03:48:34 EDT 2025
Thu Apr 24 22:59:21 EDT 2025
Fri Feb 21 02:29:12 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords Lassomycin
Teixobactin
Anti-TB
Natural products
Phage therapy
Synthetic biology
Genome mining
Mycobacterium tuberculosis
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c574t-2adea2a23512f5879b5ea0af187d53911d633b4f589b961c703a7a1bd3c3060b3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0003-3106-4085
0000-0001-9204-2694
PMID 32185432
PQID 2396098769
PQPubID 54065
PageCount 13
ParticipantIDs proquest_miscellaneous_2439431182
proquest_miscellaneous_2378897575
proquest_journals_3195323165
proquest_journals_2396098769
gale_infotracmisc_A622405762
gale_infotracacademiconefile_A622405762
gale_incontextgauss_ISR_A622405762
pubmed_primary_32185432
crossref_citationtrail_10_1007_s00253_020_10513_2
crossref_primary_10_1007_s00253_020_10513_2
springer_journals_10_1007_s00253_020_10513_2
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-05-01
PublicationDateYYYYMMDD 2020-05-01
PublicationDate_xml – month: 05
  year: 2020
  text: 2020-05-01
  day: 01
PublicationDecade 2020
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationTitle Applied microbiology and biotechnology
PublicationTitleAbbrev Appl Microbiol Biotechnol
PublicationTitleAlternate Appl Microbiol Biotechnol
PublicationYear 2020
Publisher Springer Berlin Heidelberg
Springer
Springer Nature B.V
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer
– name: Springer Nature B.V
References Dawson, Diacon, Everitt, van Niekerk, Donald, Burger, Schall, Spigelman, Conradie, Eisenach, Venter, Ive, Page-Shipp, Variava, Reither, Ntinginya, Pym, von Groote-Bidlingmaier, Mendel (CR15) 2015; 385
Diacon, Pym, Grobusch, de los Rios, Gotuzzo, Vasilyeva, Leimane, Andries, Bakare, De Marez, Haxaire-Theeuwes, Lounis, Meyvisch, De Paepe, van Heeswijk, Dannemann (CR17) 2014; 371
Imai, Meyer, Iinishi, Favre-Godal, Green, Manuse, Caboni, Mori, Niles, Ghiglieri, Honrao, Ma, Guo, Makriyannis, Linares-Otoya, Bohringer, Wuisan, Kaur, Wu, Mateus, Typas, Savitski, Espinoza, O’Rourke, Nelson, Hiller, Noinaj, Schaberle, D’Onofrio, Lewis (CR34) 2019; 576
Gavrish, Sit, Cao, Kandror, Spoering, Peoples, Ling, Fetterman, Hughes, Bissell, Torrey, Akopian, Mueller, Epstein, Goldberg, Clardy, Lewis (CR26) 2014; 21
Blower, Daley (CR4) 2002; 2
Moloney (CR53) 2016; 37
Quan, Nagalingam, Payne, Triccas (CR64) 2017; 56
Borrero, Chen, Dunny, Kaznessis (CR6) 2015; 4
Raviglione, Uplekar (CR66) 2006; 367
Doi (CR18) 2002; 50
Bressler, Zimmer, Gilmore, Somani (CR7) 2004; 4
Floss, Yu (CR23) 2005; 105
Zumla, Chakaya, Centis, D’Ambrosio, Mwaba, Bates, Kapata, Nyirenda, Chanda, Mfinanga, Hoelscher, Maeurer, Migliori (CR93) 2015; 3
Cox, Laessig (CR14) 2014; 371
Riglar, Silver (CR69) 2018; 16
Fischbach, Walsh, Clardy (CR22) 2008; 105
Koul, Arnoult, Lounis, Guillemont, Andries (CR43) 2011; 469
Quenard, Fournier, Drancourt, Brouqui (CR65) 2017; 50
Yehl, Lemire, Yang, Ando, Mimee, Torres, de la Fuente-Nunez, Lu (CR90) 2019; 179
Dornevil, Davis, Fielding, Terrell, Ma, Liu (CR19) 2017; 292
Lönnroth, Castro, Chakaya, Chauhan, Floyd, Glaziou, Raviglione (CR44) 2010; 375
Piddock (CR61) 2015; 70
Saxena, Mukherjee, Kumari, Singh, Lal (CR72) 2014; 54
Brotz-Oesterhelt, Beyer, Kroll, Endermann, Ladel, Schroeder, Hinzen, Raddatz, Paulsen, Henninger, Bandow, Sahl, Labischinski (CR8) 2005; 11
Ishizaki, Hayashi, Inoue, Igarashi, Takahashi, Pujari, Crick, Brennan, Nomoto (CR37) 2013; 288
Zhu, Su, Shams, Feng, Tong, Zheng (CR91) 2019; 103
Walsh (CR87) 2002; 3
Regeimbal, Jacobs, Corey, Henry, Thompson, Pavlicek, Quinones, Hannah, Ghebremedhin, Crane, Zurawski, Teneza-Mora, Biswas, Hall (CR67) 2016; 60
Freeman, Klutman, Lamp (CR25) 1997; 54
Cheung-Lee, Link (CR11) 2019; 46
Mandalapu, Ji, Chen, Guo, Liu, Ding, Zhou, Zhang (CR49) 2018; 83
Torgerson (CR80) 2013; 195
Andes, van Ogtrop, Peng, Craig (CR2) 2002; 46
Uplekar, Weil, Lonnroth, Jaramillo, Lienhardt, Dias, Falzon, Floyd, Gargioni, Getahun, Gilpin, Glaziou, Grzemska, Mirzayev, Nakatani, Raviglione (CR83) 2015; 385
Velásquez, van der Donk (CR85) 2011; 15
Wallis, Maeurer, Mwaba, Chakaya, Rustomjee, Migliori, Marais, Schito, Churchyard, Swaminathan, Hoelscher, Zumla (CR86) 2016; 16
CR9
Floyd, Glaziou, Zumla, Raviglione (CR24) 2018; 6
Hards, Robson, Berney, Shaw, Bald, Koul, Andries, Cook (CR29) 2015; 70
Marais, Lönnroth, Lawn, Migliori, Mwaba, Glaziou, Bates, Colagiuri, Zijenah, Swaminathan, Memish, Pletschette, Hoelscher, Abubakar, Hasan, Zafar, Pantaleo, Craig, Kim, Maeurer, Schito, Zumla (CR50) 2013; 13
CR89
Vara Prasad (CR84) 2007; 10
CR42
Menzella, Reeves (CR52) 2007; 10
CR40
Chan, Turner, Kim, Mojibian, Elefteriades, Narayan (CR10) 2018; 2018
Hegemann, Zimmermann, Xie, Marahiel (CR30) 2015; 48
Horsburgh, Barry, Lange (CR32) 2015; 373
Inokoshi, Koyama, Miyake, Shimizu, Tomoda (CR35) 2016; 6
Peek, Lilic, Montiel, Milshteyn, Woodworth, Biggins, Ternei, Calle, Danziger, Warrier, Saito, Braffman, Fay, Glickman, Darst, Campbell, Brady (CR59) 2018; 9
Ling, Schneider, Peoples, Spoering, Engels, Conlon, Mueller, Schaberle, Hughes, Epstein, Jones, Lazarides, Steadman, Cohen, Felix, Fetterman, Millett, Nitti, Zullo, Chen, Lewis (CR47) 2015; 517
Riglar, Giessen, Baym, Kerns, Niederhuber, Bronson, Kotula, Gerber, Way, Silver (CR68) 2017; 35
Su, Han, Meng, Feng, Luo, Yu, Zheng, Zhu (CR76) 2019; 103
Nigam, Almabruk, Saxena, Yang, Mukherjee, Kaur, Kohli, Kumari, Singh, Zakharov, Singh, Mahmud, Lal (CR54) 2014; 289
Shen (CR75) 2015; 163
Zumla, Gillespie, Hoelscher, Philips, Cole, Abubakar, McHugh, Schito, Maeurer, Nunn (CR94) 2014; 14
Cholo, Steel, Fourie, Germishuizen, Anderson (CR12) 2011; 67
Nikonenko, Protopopova, Samala, Einck, Nacy (CR55) 2007; 51
Piñero-Lambea, Ruano-Gallego, Fernández (CR60) 2015; 35
Schreier, Mirzoyan, Saito (CR74) 2010; 21
Keam (CR41) 2019; 79
Lodhi, Zhang, Adil, Deng (CR48) 2018; 102
Mays, Nair (CR51) 2018; 53
Tiberi, du Plessis, Walzl, Vjecha, Rao, Ntoumi, Mfinanga, Kapata, Mwaba, McHugh, Ippolito, Migliori, Maeurer, Zumla (CR79) 2018; 18
Iwatsuki, Tomoda, Uchida, Gouda, Hirono, Omura (CR38) 2006; 128
Schön, Miotto, Köser, Viveiros, Böttger, Cambau (CR73) 2017; 23
Gler, Skripconoka, Sanchez-Garavito, Xiao, Cabrera-Rivero, Vargas-Vasquez, Gao, Awad, Park, Shim, Suh, Danilovits, Ogata, Kurve, Chang, Suzuki, Tupasi, Koh, Seaworth, Geiter, Wells (CR27) 2012; 366
Zipperer, Konnerth, Laux, Berscheid, Janek, Weidenmaier, Burian, Schilling, Slavetinsky, Marschal, Willmann, Kalbacher, Schittek, Brotz-Oesterhelt, Grond, Peschel, Krismer (CR92) 2016; 535
Tyers, Wright (CR82) 2019; 17
Nobrega, Costa, Kluskens, Azeredo (CR56) 2015; 23
Ryan, Lo (CR70) 2014; 74
Clarke (CR13) 2003; 425
Al-Ghafli, Al-Hajoj (CR1) 2019; 20
Dunbar, Buttner, Molloy, Dell, Kumpfmuller, Hertweck (CR20) 2018; 57
Inokoshi, Matsuhama, Miyake, Ikeda, Tomoda (CR36) 2012; 95
Dye (CR21) 2006; 367
Letzel, Pidot, Hertweck (CR45) 2014; 15
Weber, Blin, Duddela, Krug, Kim, Bruccoleri, Lee, Fischbach, Muller, Wohlleben, Breitling, Takano, Medema (CR88) 2015; 43
Dedrick, Guerrero-Bustamante, Garlena, Russell, Ford, Harris, Gilmour, Soothill, Jacobs-Sera, Schooley, Hatfull, Spencer (CR16) 2019; 25
Guo, Mandalapu, Ji, Gao, Zhang (CR28) 2018; 24
Orme (CR58) 2001; 45
Kakkar, Dahiya (CR39) 2014; 94
Hutchinson (CR33) 1998; 1
Lincke, Behnken, Ishida, Roth, Hertweck (CR46) 2010; 49
Theuretzbacher, Gottwalt, Beyer, Butler, Czaplewski, Lienhardt, Moja, Paul, Paulin, Rex, Silver, Spigelman, Thwaites, Paccaud, Harbarth (CR78) 2019; 19
Piscotta, Tharp, Liu, Link (CR62) 2015; 51
Piton, Foo, Cole (CR63) 2017; 22
Saeidi, Wong, Lo, Nguyen, Ling, Leong, Poh, Chang (CR71) 2011; 7
Behnken, Hertweck (CR3) 2012; 96
Bologa, Ursu, Oprea, Melançon, Tegos (CR5) 2013; 13
Hoagland, Liu, Lee, Lee (CR31) 2016; 102
Tscherner, Giessen, Markey, Kumamoto, Silver (CR81) 2019; 8
Orenstein, Basu, Shah, Andrews, Friedland, Moll, Gandhi, Galvani (CR57) 2009; 9
Tahlan, Wilson, Kastrinsky, Arora, Nair, Fischer, Barnes, Walker, Alland, Barry, Boshoff (CR77) 2012; 56
MA Fischbach (10513_CR22) 2008; 105
10513_CR42
K Tahlan (10513_CR77) 2012; 56
CG Bologa (10513_CR5) 2013; 13
10513_CR89
EW Orenstein (10513_CR57) 2009; 9
10513_CR40
AK Kakkar (10513_CR39) 2014; 94
N Doi (10513_CR18) 2002; 50
M Iwatsuki (10513_CR38) 2006; 128
T Lincke (10513_CR46) 2010; 49
F Quenard (10513_CR65) 2017; 50
AH Diacon (10513_CR17) 2014; 371
10513_CR9
MC Raviglione (10513_CR66) 2006; 367
A Koul (10513_CR43) 2011; 469
AF Lodhi (10513_CR48) 2018; 102
CR Hutchinson (10513_CR33) 1998; 1
LJ Piddock (10513_CR61) 2015; 70
B Shen (10513_CR75) 2015; 163
U Theuretzbacher (10513_CR78) 2019; 19
A Zipperer (10513_CR92) 2016; 535
D Quan (10513_CR64) 2017; 56
JVN Vara Prasad (10513_CR84) 2007; 10
JE Velásquez (10513_CR85) 2011; 15
MG Moloney (10513_CR53) 2016; 37
K Floyd (10513_CR24) 2018; 6
HG Floss (10513_CR23) 2005; 105
J Peek (10513_CR59) 2018; 9
HG Menzella (10513_CR52) 2007; 10
HJ Schreier (10513_CR74) 2010; 21
MT Gler (10513_CR27) 2012; 366
DT Hoagland (10513_CR31) 2016; 102
Y Imai (10513_CR34) 2019; 576
DT Riglar (10513_CR69) 2018; 16
M Tyers (10513_CR82) 2019; 17
FJ Piscotta (10513_CR62) 2015; 51
T Schön (10513_CR73) 2017; 23
S Zhu (10513_CR91) 2019; 103
FL Nobrega (10513_CR56) 2015; 23
MC Cholo (10513_CR12) 2011; 67
N Saeidi (10513_CR71) 2011; 7
BJ Marais (10513_CR50) 2013; 13
DT Riglar (10513_CR68) 2017; 35
WL Cheung-Lee (10513_CR11) 2019; 46
A Nigam (10513_CR54) 2014; 289
BV Nikonenko (10513_CR55) 2007; 51
NJ Ryan (10513_CR70) 2014; 74
D Andes (10513_CR2) 2002; 46
CR Horsburgh (10513_CR32) 2015; 373
AM Bressler (10513_CR7) 2004; 4
K Hards (10513_CR29) 2015; 70
D Mandalapu (10513_CR49) 2018; 83
T Weber (10513_CR88) 2015; 43
R Dawson (10513_CR15) 2015; 385
JM Regeimbal (10513_CR67) 2016; 60
I Orme (10513_CR58) 2001; 45
M Tscherner (10513_CR81) 2019; 8
SM Blower (10513_CR4) 2002; 2
K Yehl (10513_CR90) 2019; 179
LL Ling (10513_CR47) 2015; 517
J Inokoshi (10513_CR36) 2012; 95
AI Zumla (10513_CR94) 2014; 14
E Gavrish (10513_CR26) 2014; 21
ZJS Mays (10513_CR51) 2018; 53
J Inokoshi (10513_CR35) 2016; 6
A Saxena (10513_CR72) 2014; 54
Y Su (10513_CR76) 2019; 103
K Lönnroth (10513_CR44) 2010; 375
J Borrero (10513_CR6) 2015; 4
Y Ishizaki (10513_CR37) 2013; 288
CD Freeman (10513_CR25) 1997; 54
C Dye (10513_CR21) 2006; 367
BK Chan (10513_CR10) 2018; 2018
RM Dedrick (10513_CR16) 2019; 25
A Zumla (10513_CR93) 2015; 3
M Uplekar (10513_CR83) 2015; 385
T Clarke (10513_CR13) 2003; 425
H Brotz-Oesterhelt (10513_CR8) 2005; 11
CT Walsh (10513_CR87) 2002; 3
J Piton (10513_CR63) 2017; 22
JD Hegemann (10513_CR30) 2015; 48
C Piñero-Lambea (10513_CR60) 2015; 35
S Tiberi (10513_CR79) 2018; 18
AC Letzel (10513_CR45) 2014; 15
S Behnken (10513_CR3) 2012; 96
E Cox (10513_CR14) 2014; 371
RS Wallis (10513_CR86) 2016; 16
C Guo (10513_CR28) 2018; 24
H Al-Ghafli (10513_CR1) 2019; 20
K Dornevil (10513_CR19) 2017; 292
SJ Keam (10513_CR41) 2019; 79
KL Dunbar (10513_CR20) 2018; 57
PR Torgerson (10513_CR80) 2013; 195
References_xml – volume: 292
  start-page: 13645
  issue: 33
  year: 2017
  end-page: 13657
  ident: CR19
  article-title: Cross-linking of dicyclotyrosine by the cytochrome P450 enzyme CYP121 from proceeds through a catalytic shunt pathway
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M117.794099
– volume: 102
  start-page: 55
  year: 2016
  end-page: 72
  ident: CR31
  article-title: New agents for the treatment of drug-resistant
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2016.04.026
– volume: 105
  start-page: 621
  issue: 2
  year: 2005
  end-page: 632
  ident: CR23
  article-title: Rifamycin mode of action, resistance, and biosynthesis
  publication-title: Chem Rev
  doi: 10.1021/cr030112j
– volume: 46
  start-page: 1371
  issue: 9
  year: 2019
  end-page: 1379
  ident: CR11
  article-title: Genome mining for lasso peptides: past, present, and future
  publication-title: J Ind Microbiol Biotechnol
  doi: 10.1007/s10295-019-02197-z
– volume: 385
  start-page: 1738
  issue: 9979
  year: 2015
  end-page: 1747
  ident: CR15
  article-title: Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis
  publication-title: Lancet
  doi: 10.1016/S0140-6736(14)62002-X
– volume: 24
  start-page: 5406
  issue: 21
  year: 2018
  end-page: 5422
  ident: CR28
  article-title: Chemistry and biology of teixobactin
  publication-title: Chemistry
  doi: 10.1002/chem.201704167
– volume: 49
  start-page: 2011
  issue: 11
  year: 2010
  end-page: 2013
  ident: CR46
  article-title: Closthioamide: an unprecedented polythioamide antibiotic from the strictly anaerobic bacterium
  publication-title: Angew Chem Int Ed Eng
  doi: 10.1002/anie.200906114
– volume: 179
  start-page: 459
  issue: 2
  year: 2019
  end-page: 469
  ident: CR90
  article-title: Engineering phage host-range and suppressing bacterial resistance through phage tail fiber mutagenesis
  publication-title: Cell
  doi: 10.1016/j.cell.2019.09.015
– volume: 11
  start-page: 1082
  issue: 10
  year: 2005
  end-page: 1087
  ident: CR8
  article-title: Dysregulation of bacterial proteolytic machinery by a new class of antibiotics
  publication-title: Nat Med
  doi: 10.1038/nm1306
– volume: 35
  start-page: 653
  issue: 7
  year: 2017
  end-page: 658
  ident: CR68
  article-title: Engineered bacteria can function in the mammalian gut long-term as live diagnostics of inflammation
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.3879
– volume: 19
  start-page: e40
  issue: 2
  year: 2019
  end-page: e50
  ident: CR78
  article-title: Analysis of the clinical antibacterial and antituberculosis pipeline
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(18)30513-9
– volume: 17
  start-page: 141
  issue: 3
  year: 2019
  end-page: 155
  ident: CR82
  article-title: Drug combinations: a strategy to extend the life of antibiotics in the 21st century
  publication-title: Nat Rev Microbiol
  doi: 10.1038/s41579-018-0141-x
– volume: 8
  start-page: 434
  issue: 2
  year: 2019
  end-page: 444
  ident: CR81
  article-title: A synthetic system that senses and inhibits virulence factors
  publication-title: ACS Synth Biol
  doi: 10.1021/acssynbio.8b00457
– volume: 21
  start-page: 509
  issue: 4
  year: 2014
  end-page: 518
  ident: CR26
  article-title: Lassomycin, a ribosomally synthesized cyclic peptide, kills by targeting the ATP-dependent protease ClpC1P1P2
  publication-title: Chem Biol
  doi: 10.1016/j.chembiol.2014.01.014
– volume: 67
  start-page: 290
  issue: 2
  year: 2011
  end-page: 298
  ident: CR12
  article-title: Clofazimine: current status and future prospects
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkr444
– volume: 15
  start-page: 983
  year: 2014
  ident: CR45
  article-title: Genome mining for ribosomally synthesized and post-translationally modified peptides (RiPPs) in anaerobic bacteria
  publication-title: BMC Genomics
  doi: 10.1186/1471-2164-15-983
– volume: 45
  start-page: 1943
  issue: 7
  year: 2001
  end-page: 1946
  ident: CR58
  article-title: Search for new drugs for treatment of tuberculosis
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.45.7.1943-1946.2001
– volume: 22
  start-page: 526
  issue: 3
  year: 2017
  end-page: 533
  ident: CR63
  article-title: Structural studies of DprE1 interacting with its inhibitors
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2016.09.014
– volume: 103
  start-page: 2649
  issue: 6
  year: 2019
  end-page: 2664
  ident: CR76
  article-title: Discovery and characterization of a novel C-terminal peptide carboxyl methyltransferase in a lassomycin-like lasso peptide biosynthetic pathway
  publication-title: Appl Microbiol Biotechnol
  doi: 10.1007/s00253-019-09645-x
– volume: 48
  start-page: 1909
  issue: 7
  year: 2015
  end-page: 1919
  ident: CR30
  article-title: Lasso peptides: an intriguing class of bacterial natural products
  publication-title: Acc Chem Res
  doi: 10.1021/acs.accounts.5b00156
– volume: 18
  start-page: e183
  issue: 7
  year: 2018
  end-page: e198
  ident: CR79
  article-title: Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapies
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(18)30110-5
– volume: 10
  start-page: 454
  issue: 5
  year: 2007
  end-page: 460
  ident: CR84
  article-title: New oxazolidinones
  publication-title: Curr Opin Microbiol
  doi: 10.1016/j.mib.2007.08.001
– volume: 128
  start-page: 7486
  issue: 23
  year: 2006
  end-page: 7491
  ident: CR38
  article-title: Lariatins, antimycobacterial peptides produced by sp. K01-B0171, have a lasso structure
  publication-title: J Am Chem Soc
  doi: 10.1021/ja056780z
– volume: 53
  start-page: 224
  year: 2018
  end-page: 231
  ident: CR51
  article-title: Synthetic biology in probiotic lactic acid bacteria: at the frontier of living therapeutics
  publication-title: Curr Opin Biotechnol
  doi: 10.1016/j.copbio.2018.01.028
– ident: CR42
– volume: 54
  start-page: 369
  issue: 4
  year: 2014
  end-page: 375
  ident: CR72
  article-title: Synthetic biology in action: developing a drug against MDR-TB
  publication-title: Indian J Microbiol
  doi: 10.1007/s12088-014-0498-0
– volume: 50
  start-page: 767
  year: 2002
  end-page: 776
  ident: CR18
  article-title: Current status in the development of the new anti-tuberculosis drugs
  publication-title: JPN J Chemotherapy
– volume: 3
  start-page: 220
  issue: 3
  year: 2015
  end-page: 234
  ident: CR93
  article-title: Tuberculosis treatment and management—an update on treatment regimens, trials, new drugs, and adjunct therapies
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(15)00063-6
– volume: 288
  start-page: 30309
  issue: 42
  year: 2013
  end-page: 30319
  ident: CR37
  article-title: Inhibition of the first step in synthesis of the mycobacterial cell wall core, catalyzed by the GlcNAc-1-phosphate transferase WecA, by the novel caprazamycin derivative CPZEN-45
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M113.492173
– volume: 10
  start-page: 238
  issue: 3
  year: 2007
  end-page: 245
  ident: CR52
  article-title: Combinatorial biosynthesis for drug development
  publication-title: Curr Opin Microbiol
  doi: 10.1016/j.mib.2007.05.005
– volume: 103
  start-page: 3931
  issue: 10
  year: 2019
  end-page: 3940
  ident: CR91
  article-title: Lassomycin and lariatin lasso peptides as suitable antibiotics for combating mycobacterial infections: current state of biosynthesis and perspectives for production
  publication-title: Appl Microbiol Biotechnol
  doi: 10.1007/s00253-019-09771-6
– volume: 371
  start-page: 723
  issue: 8
  year: 2014
  end-page: 732
  ident: CR17
  article-title: Multidrug-resistant tuberculosis and culture conversion with bedaquiline
  publication-title: N Engl J Med
  doi: 10.1056/Nejmoa1313865
– volume: 375
  start-page: 1814
  issue: 9728
  year: 2010
  end-page: 1829
  ident: CR44
  article-title: Tuberculosis control and elimination 2010–50: cure, care, and social development
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)60483-7
– volume: 3
  start-page: 124
  issue: 2–3
  year: 2002
  end-page: 134
  ident: CR87
  article-title: Combinatorial biosynthesis of antibiotics: challenges and opportunities
  publication-title: Chembiochem
  doi: 10.1002/1439-7633(20020301)3:2/3<124::aid-cbic124>3.0.co;2-j
– volume: 23
  start-page: 154
  issue: 3
  year: 2017
  end-page: 160
  ident: CR73
  article-title: drug-resistance testing: challenges, recent developments and perspectives
  publication-title: Clin Microbiol Infect
  doi: 10.1016/j.cmi.2016.10.022
– volume: 535
  start-page: 511
  issue: 7613
  year: 2016
  end-page: 516
  ident: CR92
  article-title: Human commensals producing a novel antibiotic impair pathogen colonization
  publication-title: Nature
  doi: 10.1038/nature18634
– volume: 6
  start-page: 30375
  year: 2016
  ident: CR35
  article-title: Structure-activity analysis of Gram-positive bacterium-producing lasso peptides with anti-mycobacterial activity
  publication-title: Sci Rep
  doi: 10.1038/srep30375
– volume: 94
  start-page: 357
  issue: 4
  year: 2014
  end-page: 362
  ident: CR39
  article-title: Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls
  publication-title: Tuberculosis (Edinb)
  doi: 10.1016/j.tube.2014.04.001
– volume: 70
  start-page: 2028
  issue: 7
  year: 2015
  end-page: 2037
  ident: CR29
  article-title: Bactericidal mode of action of bedaquiline
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkv054
– volume: 83
  start-page: 7271
  issue: 13
  year: 2018
  end-page: 7275
  ident: CR49
  article-title: Thioesterase-mediated synthesis of teixobactin analogues: mechanism and substrate specificity
  publication-title: J Organomet Chem
  doi: 10.1021/acs.joc.7b02462
– volume: 43
  start-page: W237
  issue: W1
  year: 2015
  end-page: W243
  ident: CR88
  article-title: antiSMASH 3.0-a comprehensive resource for the genome mining of biosynthetic gene clusters
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkv437
– volume: 6
  start-page: 299
  issue: 4
  year: 2018
  end-page: 314
  ident: CR24
  article-title: The global tuberculosis epidemic and progress in care, prevention, and research: an overview in year 3 of the End TB era
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(18)30057-2
– volume: 366
  start-page: 2151
  issue: 23
  year: 2012
  end-page: 2160
  ident: CR27
  article-title: Delamanid for multidrug-resistant pulmonary tuberculosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1112433
– volume: 35
  start-page: 94
  year: 2015
  end-page: 102
  ident: CR60
  article-title: Engineered bacteria as therapeutic agents
  publication-title: Curr Opin Biotechnol
  doi: 10.1016/j.copbio.2015.05.004
– ident: CR9
– volume: 95
  start-page: 451
  issue: 2
  year: 2012
  end-page: 460
  ident: CR36
  article-title: Molecular cloning of the gene cluster for lariatin biosynthesis of K01-B0171
  publication-title: Appl Microbiol Biotechnol
  doi: 10.1007/s00253-012-3973-8
– volume: 51
  start-page: 409
  issue: 2
  year: 2015
  end-page: 412
  ident: CR62
  article-title: Expanding the chemical diversity of lasso peptide MccJ25 with genetically encoded noncanonical amino acids
  publication-title: Chem Commun (Camb)
  doi: 10.1039/C4CC07778D
– volume: 74
  start-page: 1041
  issue: 9
  year: 2014
  end-page: 1045
  ident: CR70
  article-title: Delamanid: first global approval
  publication-title: Drugs
  doi: 10.1007/s40265-014-0241-5
– volume: 195
  start-page: 223
  issue: 3
  year: 2013
  end-page: 232
  ident: CR80
  article-title: One world health: socioeconomic burden and parasitic disease control priorities
  publication-title: Vet Parasitol
  doi: 10.1016/j.vetpar.2013.04.004
– volume: 469
  start-page: 483
  issue: 7331
  year: 2011
  end-page: 490
  ident: CR43
  article-title: The challenge of new drug discovery for tuberculosis
  publication-title: Nature
  doi: 10.1038/nature09657
– volume: 163
  start-page: 1297
  issue: 6
  year: 2015
  end-page: 1300
  ident: CR75
  article-title: A new golden age of natural products drug discovery
  publication-title: Cell
  doi: 10.1016/j.cell.2015.11.031
– volume: 16
  start-page: 214
  issue: 4
  year: 2018
  end-page: 225
  ident: CR69
  article-title: Engineering bacteria for diagnostic and therapeutic applications
  publication-title: Nat Rev Microbiol
  doi: 10.1038/nrmicro.2017.172
– volume: 576
  start-page: 459
  year: 2019
  end-page: 464
  ident: CR34
  article-title: A new antibiotic selectively kills Gram-negative pathogens
  publication-title: Nature
  doi: 10.1038/s41586-019-1791-1
– volume: 21
  start-page: 318
  issue: 3
  year: 2010
  end-page: 325
  ident: CR74
  article-title: Microbial diversity of biological filters in recirculating aquaculture systems
  publication-title: Curr Opin Biotechnol
  doi: 10.1016/j.copbio.2010.03.011
– volume: 2
  start-page: 374
  issue: 6
  year: 2002
  end-page: 376
  ident: CR4
  article-title: Problems and solutions for the Stop TB partnership
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(02)00292-X
– volume: 60
  start-page: 5806
  issue: 10
  year: 2016
  end-page: 5816
  ident: CR67
  article-title: Personalized therapeutic cocktail of wild environmental phages rescues mice from wound infections
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/aac.02877-15
– ident: CR89
– volume: 367
  start-page: 952
  issue: 9514
  year: 2006
  end-page: 955
  ident: CR66
  article-title: WHO’s new Stop TB strategy
  publication-title: Lancet
  doi: 10.1016/S0140-6736(06)68392-X
– volume: 56
  start-page: 1797
  issue: 4
  year: 2012
  end-page: 1809
  ident: CR77
  article-title: SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/aac.05708-11
– volume: 70
  start-page: 2679
  issue: 10
  year: 2015
  end-page: 2680
  ident: CR61
  article-title: Teixobactin, the first of a new class of antibiotics discovered by iChip technology?
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkv175
– volume: 13
  start-page: 678
  issue: 5
  year: 2013
  end-page: 687
  ident: CR5
  article-title: Emerging trends in the discovery of natural product antibacterials
  publication-title: Curr Opin Pharmacol
  doi: 10.1016/j.coph.2013.07.002
– volume: 367
  start-page: 938
  issue: 9514
  year: 2006
  end-page: 940
  ident: CR21
  article-title: Global epidemiology of tuberculosis
  publication-title: Lancet
  doi: 10.1016/S0140-6736(06)68384-0
– volume: 15
  start-page: 11
  issue: 1
  year: 2011
  end-page: 21
  ident: CR85
  article-title: Genome mining for ribosomally synthesized natural products
  publication-title: Curr Opin Chem Biol
  doi: 10.1016/j.cbpa.2010.10.027
– volume: 20
  start-page: 272
  issue: 4
  year: 2019
  end-page: 284
  ident: CR1
  article-title: Clinical management of drug-resistant strains: pathogen-targeted versus host-directed treatment approaches
  publication-title: Curr Pharm Biotechnol
  doi: 10.2174/1389201019666180731120544
– ident: CR40
– volume: 4
  start-page: 528
  issue: 8
  year: 2004
  end-page: 531
  ident: CR7
  article-title: Peripheral neuropathy associated with prolonged use of linezolid
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(04)01109-0
– volume: 57
  start-page: 14080
  issue: 43
  year: 2018
  end-page: 14084
  ident: CR20
  article-title: Genome editing reveals novel thiotemplated assembly of polythioamide antibiotics in anaerobic bacteria
  publication-title: Angew Chem Int Ed Eng
  doi: 10.1002/anie.201807970
– volume: 373
  start-page: 2149
  issue: 22
  year: 2015
  end-page: 2160
  ident: CR32
  article-title: Treatment of Tuberculosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra1413919
– volume: 102
  start-page: 7333
  issue: 17
  year: 2018
  end-page: 7341
  ident: CR48
  article-title: Antibiotic discovery: combining isolation chip (iChip) technology and co-culture technique
  publication-title: Appl Microbiol Biotechnol
  doi: 10.1007/s00253-018-9193-0
– volume: 51
  start-page: 1563
  issue: 4
  year: 2007
  end-page: 1565
  ident: CR55
  article-title: Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new Diamine antibiotic, with existing TB drugs
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/aac.01326-06
– volume: 9
  start-page: 153
  issue: 3
  year: 2009
  end-page: 161
  ident: CR57
  article-title: Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(09)70041-6
– volume: 9
  start-page: 4147
  issue: 1
  year: 2018
  end-page: 4115
  ident: CR59
  article-title: Rifamycin congeners kanglemycins are active against rifampicin-resistant bacteria via a distinct mechanism
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-06587-2
– volume: 105
  start-page: 4601
  issue: 12
  year: 2008
  end-page: 4608
  ident: CR22
  article-title: The evolution of gene collectives: how natural selection drives chemical innovation
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0709132105
– volume: 37
  start-page: 689
  issue: 8
  year: 2016
  end-page: 701
  ident: CR53
  article-title: Natural products as a source for novel antibiotics
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2016.05.001
– volume: 7
  start-page: 521
  issue: 1
  year: 2011
  ident: CR71
  article-title: Engineering microbes to sense and eradicate , a human pathogen
  publication-title: Mol Syst Biol
  doi: 10.1038/msb.2011.55
– volume: 46
  start-page: 3484
  issue: 11
  year: 2002
  end-page: 3489
  ident: CR2
  article-title: In vivo pharmacodynamics of a new oxazolidinone (linezolid)
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/aac.46.11.3484-3489.2002
– volume: 425
  start-page: 225
  issue: 6955
  year: 2003
  ident: CR13
  article-title: Drug companies snub antibiotics as pipeline threatens to run dry
  publication-title: Nature
  doi: 10.1038/425225a
– volume: 13
  start-page: 436
  issue: 5
  year: 2013
  end-page: 448
  ident: CR50
  article-title: Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(13)70015-X
– volume: 16
  start-page: e34
  issue: 4
  year: 2016
  end-page: e46
  ident: CR86
  article-title: Tuberculosis—advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(16)00070-0
– volume: 56
  start-page: 212
  year: 2017
  end-page: 220
  ident: CR64
  article-title: New tuberculosis drug leads from naturally occurring compounds
  publication-title: Int J Infect Dis
  doi: 10.1016/j.ijid.2016.12.024
– volume: 4
  start-page: 299
  issue: 3
  year: 2015
  end-page: 306
  ident: CR6
  article-title: Modified lactic acid bacteria detect and inhibit multiresistant enterococci
  publication-title: ACS Synth Biol
  doi: 10.1021/sb500090b
– volume: 54
  start-page: 679
  issue: 5
  year: 1997
  end-page: 708
  ident: CR25
  article-title: Metronidazole
  publication-title: Drugs
  doi: 10.2165/00003495-199754050-00003
– volume: 23
  start-page: 185
  issue: 4
  year: 2015
  end-page: 191
  ident: CR56
  article-title: Revisiting phage therapy: new applications for old resources
  publication-title: Trends Microbiol
  doi: 10.1016/j.tim.2015.01.006
– volume: 517
  start-page: 455
  issue: 7535
  year: 2015
  end-page: 459
  ident: CR47
  article-title: A new antibiotic kills pathogens without detectable resistance
  publication-title: Nature
  doi: 10.1038/nature14098
– volume: 2018
  start-page: 60
  issue: 1
  year: 2018
  end-page: 66
  ident: CR10
  article-title: Phage treatment of an aortic graft infected with
  publication-title: Evol Med Public Health
  doi: 10.1093/emph/eoy005
– volume: 1
  start-page: 319
  issue: 3
  year: 1998
  end-page: 329
  ident: CR33
  article-title: Combinatorial biosynthesis for new drug discovery
  publication-title: Curr Opin Microbiol
  doi: 10.1016/S1369-5274(98)80036-2
– volume: 50
  start-page: 252
  issue: 2
  year: 2017
  end-page: 254
  ident: CR65
  article-title: Role of second-line injectable antituberculosis drugs in the treatment of MDR/XDR tuberculosis
  publication-title: Int J Antimicrob Agents
  doi: 10.1016/j.ijantimicag.2017.01.042
– volume: 14
  start-page: 327
  issue: 4
  year: 2014
  end-page: 340
  ident: CR94
  article-title: New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(13)70328-1
– volume: 25
  start-page: 730
  issue: 5
  year: 2019
  end-page: 733
  ident: CR16
  article-title: Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant
  publication-title: Nat Med
  doi: 10.1038/s41591-019-0437-z
– volume: 385
  start-page: 1799
  issue: 9979
  year: 2015
  end-page: 1801
  ident: CR83
  article-title: WHO’s new End TB strategy
  publication-title: Lancet
  doi: 10.1016/S0140-6736(15)60570-0
– volume: 79
  start-page: 1797
  issue: 16
  year: 2019
  end-page: 1803
  ident: CR41
  article-title: Pretomanid: first approval
  publication-title: Drugs
  doi: 10.1007/s40265-019-01207-9
– volume: 289
  start-page: 21142
  issue: 30
  year: 2014
  end-page: 21152
  ident: CR54
  article-title: Modification of rifamycin polyketide backbone leads to improved drug activity against rifampicin-resistant
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M114.572636
– volume: 371
  start-page: 689
  issue: 8
  year: 2014
  end-page: 691
  ident: CR14
  article-title: FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMp1314385
– volume: 96
  start-page: 61
  issue: 1
  year: 2012
  end-page: 67
  ident: CR3
  article-title: Anaerobic bacteria as producers of antibiotics
  publication-title: Appl Microbiol Biotechnol
  doi: 10.1007/s00253-012-4285-8
– volume: 57
  start-page: 14080
  issue: 43
  year: 2018
  ident: 10513_CR20
  publication-title: Angew Chem Int Ed Eng
  doi: 10.1002/anie.201807970
– volume: 10
  start-page: 454
  issue: 5
  year: 2007
  ident: 10513_CR84
  publication-title: Curr Opin Microbiol
  doi: 10.1016/j.mib.2007.08.001
– volume: 6
  start-page: 30375
  year: 2016
  ident: 10513_CR35
  publication-title: Sci Rep
  doi: 10.1038/srep30375
– volume: 13
  start-page: 436
  issue: 5
  year: 2013
  ident: 10513_CR50
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(13)70015-X
– volume: 103
  start-page: 3931
  issue: 10
  year: 2019
  ident: 10513_CR91
  publication-title: Appl Microbiol Biotechnol
  doi: 10.1007/s00253-019-09771-6
– volume: 16
  start-page: 214
  issue: 4
  year: 2018
  ident: 10513_CR69
  publication-title: Nat Rev Microbiol
  doi: 10.1038/nrmicro.2017.172
– volume: 22
  start-page: 526
  issue: 3
  year: 2017
  ident: 10513_CR63
  publication-title: Drug Discov Today
  doi: 10.1016/j.drudis.2016.09.014
– volume: 23
  start-page: 154
  issue: 3
  year: 2017
  ident: 10513_CR73
  publication-title: Clin Microbiol Infect
  doi: 10.1016/j.cmi.2016.10.022
– volume: 54
  start-page: 679
  issue: 5
  year: 1997
  ident: 10513_CR25
  publication-title: Drugs
  doi: 10.2165/00003495-199754050-00003
– volume: 9
  start-page: 153
  issue: 3
  year: 2009
  ident: 10513_CR57
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(09)70041-6
– volume: 53
  start-page: 224
  year: 2018
  ident: 10513_CR51
  publication-title: Curr Opin Biotechnol
  doi: 10.1016/j.copbio.2018.01.028
– volume: 45
  start-page: 1943
  issue: 7
  year: 2001
  ident: 10513_CR58
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/AAC.45.7.1943-1946.2001
– ident: 10513_CR40
  doi: 10.1111/nyas.14282
– volume: 79
  start-page: 1797
  issue: 16
  year: 2019
  ident: 10513_CR41
  publication-title: Drugs
  doi: 10.1007/s40265-019-01207-9
– volume: 37
  start-page: 689
  issue: 8
  year: 2016
  ident: 10513_CR53
  publication-title: Trends Pharmacol Sci
  doi: 10.1016/j.tips.2016.05.001
– volume: 49
  start-page: 2011
  issue: 11
  year: 2010
  ident: 10513_CR46
  publication-title: Angew Chem Int Ed Eng
  doi: 10.1002/anie.200906114
– volume: 292
  start-page: 13645
  issue: 33
  year: 2017
  ident: 10513_CR19
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M117.794099
– volume: 48
  start-page: 1909
  issue: 7
  year: 2015
  ident: 10513_CR30
  publication-title: Acc Chem Res
  doi: 10.1021/acs.accounts.5b00156
– volume: 94
  start-page: 357
  issue: 4
  year: 2014
  ident: 10513_CR39
  publication-title: Tuberculosis (Edinb)
  doi: 10.1016/j.tube.2014.04.001
– volume: 35
  start-page: 94
  year: 2015
  ident: 10513_CR60
  publication-title: Curr Opin Biotechnol
  doi: 10.1016/j.copbio.2015.05.004
– volume: 195
  start-page: 223
  issue: 3
  year: 2013
  ident: 10513_CR80
  publication-title: Vet Parasitol
  doi: 10.1016/j.vetpar.2013.04.004
– volume: 43
  start-page: W237
  issue: W1
  year: 2015
  ident: 10513_CR88
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkv437
– volume: 13
  start-page: 678
  issue: 5
  year: 2013
  ident: 10513_CR5
  publication-title: Curr Opin Pharmacol
  doi: 10.1016/j.coph.2013.07.002
– volume: 18
  start-page: e183
  issue: 7
  year: 2018
  ident: 10513_CR79
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(18)30110-5
– volume: 96
  start-page: 61
  issue: 1
  year: 2012
  ident: 10513_CR3
  publication-title: Appl Microbiol Biotechnol
  doi: 10.1007/s00253-012-4285-8
– volume: 25
  start-page: 730
  issue: 5
  year: 2019
  ident: 10513_CR16
  publication-title: Nat Med
  doi: 10.1038/s41591-019-0437-z
– volume: 56
  start-page: 212
  year: 2017
  ident: 10513_CR64
  publication-title: Int J Infect Dis
  doi: 10.1016/j.ijid.2016.12.024
– ident: 10513_CR42
  doi: 10.1007/978-981-32-9413-4_25
– volume: 373
  start-page: 2149
  issue: 22
  year: 2015
  ident: 10513_CR32
  publication-title: N Engl J Med
  doi: 10.1056/NEJMra1413919
– volume: 46
  start-page: 1371
  issue: 9
  year: 2019
  ident: 10513_CR11
  publication-title: J Ind Microbiol Biotechnol
  doi: 10.1007/s10295-019-02197-z
– volume: 385
  start-page: 1799
  issue: 9979
  year: 2015
  ident: 10513_CR83
  publication-title: Lancet
  doi: 10.1016/S0140-6736(15)60570-0
– volume: 6
  start-page: 299
  issue: 4
  year: 2018
  ident: 10513_CR24
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(18)30057-2
– volume: 163
  start-page: 1297
  issue: 6
  year: 2015
  ident: 10513_CR75
  publication-title: Cell
  doi: 10.1016/j.cell.2015.11.031
– volume: 15
  start-page: 11
  issue: 1
  year: 2011
  ident: 10513_CR85
  publication-title: Curr Opin Chem Biol
  doi: 10.1016/j.cbpa.2010.10.027
– volume: 21
  start-page: 509
  issue: 4
  year: 2014
  ident: 10513_CR26
  publication-title: Chem Biol
  doi: 10.1016/j.chembiol.2014.01.014
– volume: 9
  start-page: 4147
  issue: 1
  year: 2018
  ident: 10513_CR59
  publication-title: Nat Commun
  doi: 10.1038/s41467-018-06587-2
– volume: 3
  start-page: 220
  issue: 3
  year: 2015
  ident: 10513_CR93
  publication-title: Lancet Respir Med
  doi: 10.1016/S2213-2600(15)00063-6
– volume: 367
  start-page: 952
  issue: 9514
  year: 2006
  ident: 10513_CR66
  publication-title: Lancet
  doi: 10.1016/S0140-6736(06)68392-X
– volume: 70
  start-page: 2679
  issue: 10
  year: 2015
  ident: 10513_CR61
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkv175
– volume: 367
  start-page: 938
  issue: 9514
  year: 2006
  ident: 10513_CR21
  publication-title: Lancet
  doi: 10.1016/S0140-6736(06)68384-0
– volume: 375
  start-page: 1814
  issue: 9728
  year: 2010
  ident: 10513_CR44
  publication-title: Lancet
  doi: 10.1016/S0140-6736(10)60483-7
– volume: 517
  start-page: 455
  issue: 7535
  year: 2015
  ident: 10513_CR47
  publication-title: Nature
  doi: 10.1038/nature14098
– volume: 74
  start-page: 1041
  issue: 9
  year: 2014
  ident: 10513_CR70
  publication-title: Drugs
  doi: 10.1007/s40265-014-0241-5
– volume: 50
  start-page: 252
  issue: 2
  year: 2017
  ident: 10513_CR65
  publication-title: Int J Antimicrob Agents
  doi: 10.1016/j.ijantimicag.2017.01.042
– ident: 10513_CR89
– volume: 385
  start-page: 1738
  issue: 9979
  year: 2015
  ident: 10513_CR15
  publication-title: Lancet
  doi: 10.1016/S0140-6736(14)62002-X
– volume: 366
  start-page: 2151
  issue: 23
  year: 2012
  ident: 10513_CR27
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1112433
– volume: 102
  start-page: 7333
  issue: 17
  year: 2018
  ident: 10513_CR48
  publication-title: Appl Microbiol Biotechnol
  doi: 10.1007/s00253-018-9193-0
– volume: 4
  start-page: 299
  issue: 3
  year: 2015
  ident: 10513_CR6
  publication-title: ACS Synth Biol
  doi: 10.1021/sb500090b
– volume: 46
  start-page: 3484
  issue: 11
  year: 2002
  ident: 10513_CR2
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/aac.46.11.3484-3489.2002
– volume: 83
  start-page: 7271
  issue: 13
  year: 2018
  ident: 10513_CR49
  publication-title: J Organomet Chem
  doi: 10.1021/acs.joc.7b02462
– volume: 51
  start-page: 1563
  issue: 4
  year: 2007
  ident: 10513_CR55
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/aac.01326-06
– volume: 20
  start-page: 272
  issue: 4
  year: 2019
  ident: 10513_CR1
  publication-title: Curr Pharm Biotechnol
  doi: 10.2174/1389201019666180731120544
– volume: 15
  start-page: 983
  year: 2014
  ident: 10513_CR45
  publication-title: BMC Genomics
  doi: 10.1186/1471-2164-15-983
– volume: 19
  start-page: e40
  issue: 2
  year: 2019
  ident: 10513_CR78
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(18)30513-9
– volume: 50
  start-page: 767
  year: 2002
  ident: 10513_CR18
  publication-title: JPN J Chemotherapy
– volume: 8
  start-page: 434
  issue: 2
  year: 2019
  ident: 10513_CR81
  publication-title: ACS Synth Biol
  doi: 10.1021/acssynbio.8b00457
– volume: 535
  start-page: 511
  issue: 7613
  year: 2016
  ident: 10513_CR92
  publication-title: Nature
  doi: 10.1038/nature18634
– volume: 2
  start-page: 374
  issue: 6
  year: 2002
  ident: 10513_CR4
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(02)00292-X
– volume: 10
  start-page: 238
  issue: 3
  year: 2007
  ident: 10513_CR52
  publication-title: Curr Opin Microbiol
  doi: 10.1016/j.mib.2007.05.005
– volume: 17
  start-page: 141
  issue: 3
  year: 2019
  ident: 10513_CR82
  publication-title: Nat Rev Microbiol
  doi: 10.1038/s41579-018-0141-x
– volume: 128
  start-page: 7486
  issue: 23
  year: 2006
  ident: 10513_CR38
  publication-title: J Am Chem Soc
  doi: 10.1021/ja056780z
– volume: 14
  start-page: 327
  issue: 4
  year: 2014
  ident: 10513_CR94
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(13)70328-1
– volume: 56
  start-page: 1797
  issue: 4
  year: 2012
  ident: 10513_CR77
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/aac.05708-11
– ident: 10513_CR9
  doi: 10.1128/CMR.00060-17
– volume: 289
  start-page: 21142
  issue: 30
  year: 2014
  ident: 10513_CR54
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M114.572636
– volume: 67
  start-page: 290
  issue: 2
  year: 2011
  ident: 10513_CR12
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkr444
– volume: 179
  start-page: 459
  issue: 2
  year: 2019
  ident: 10513_CR90
  publication-title: Cell
  doi: 10.1016/j.cell.2019.09.015
– volume: 1
  start-page: 319
  issue: 3
  year: 1998
  ident: 10513_CR33
  publication-title: Curr Opin Microbiol
  doi: 10.1016/S1369-5274(98)80036-2
– volume: 288
  start-page: 30309
  issue: 42
  year: 2013
  ident: 10513_CR37
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M113.492173
– volume: 105
  start-page: 621
  issue: 2
  year: 2005
  ident: 10513_CR23
  publication-title: Chem Rev
  doi: 10.1021/cr030112j
– volume: 371
  start-page: 723
  issue: 8
  year: 2014
  ident: 10513_CR17
  publication-title: N Engl J Med
  doi: 10.1056/Nejmoa1313865
– volume: 2018
  start-page: 60
  issue: 1
  year: 2018
  ident: 10513_CR10
  publication-title: Evol Med Public Health
  doi: 10.1093/emph/eoy005
– volume: 54
  start-page: 369
  issue: 4
  year: 2014
  ident: 10513_CR72
  publication-title: Indian J Microbiol
  doi: 10.1007/s12088-014-0498-0
– volume: 425
  start-page: 225
  issue: 6955
  year: 2003
  ident: 10513_CR13
  publication-title: Nature
  doi: 10.1038/425225a
– volume: 7
  start-page: 521
  issue: 1
  year: 2011
  ident: 10513_CR71
  publication-title: Mol Syst Biol
  doi: 10.1038/msb.2011.55
– volume: 102
  start-page: 55
  year: 2016
  ident: 10513_CR31
  publication-title: Adv Drug Deliv Rev
  doi: 10.1016/j.addr.2016.04.026
– volume: 21
  start-page: 318
  issue: 3
  year: 2010
  ident: 10513_CR74
  publication-title: Curr Opin Biotechnol
  doi: 10.1016/j.copbio.2010.03.011
– volume: 4
  start-page: 528
  issue: 8
  year: 2004
  ident: 10513_CR7
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(04)01109-0
– volume: 95
  start-page: 451
  issue: 2
  year: 2012
  ident: 10513_CR36
  publication-title: Appl Microbiol Biotechnol
  doi: 10.1007/s00253-012-3973-8
– volume: 11
  start-page: 1082
  issue: 10
  year: 2005
  ident: 10513_CR8
  publication-title: Nat Med
  doi: 10.1038/nm1306
– volume: 70
  start-page: 2028
  issue: 7
  year: 2015
  ident: 10513_CR29
  publication-title: J Antimicrob Chemother
  doi: 10.1093/jac/dkv054
– volume: 60
  start-page: 5806
  issue: 10
  year: 2016
  ident: 10513_CR67
  publication-title: Antimicrob Agents Chemother
  doi: 10.1128/aac.02877-15
– volume: 469
  start-page: 483
  issue: 7331
  year: 2011
  ident: 10513_CR43
  publication-title: Nature
  doi: 10.1038/nature09657
– volume: 105
  start-page: 4601
  issue: 12
  year: 2008
  ident: 10513_CR22
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0709132105
– volume: 24
  start-page: 5406
  issue: 21
  year: 2018
  ident: 10513_CR28
  publication-title: Chemistry
  doi: 10.1002/chem.201704167
– volume: 51
  start-page: 409
  issue: 2
  year: 2015
  ident: 10513_CR62
  publication-title: Chem Commun (Camb)
  doi: 10.1039/C4CC07778D
– volume: 3
  start-page: 124
  issue: 2–3
  year: 2002
  ident: 10513_CR87
  publication-title: Chembiochem
  doi: 10.1002/1439-7633(20020301)3:2/3<124::aid-cbic124>3.0.co;2-j
– volume: 371
  start-page: 689
  issue: 8
  year: 2014
  ident: 10513_CR14
  publication-title: N Engl J Med
  doi: 10.1056/NEJMp1314385
– volume: 576
  start-page: 459
  year: 2019
  ident: 10513_CR34
  publication-title: Nature
  doi: 10.1038/s41586-019-1791-1
– volume: 35
  start-page: 653
  issue: 7
  year: 2017
  ident: 10513_CR68
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.3879
– volume: 103
  start-page: 2649
  issue: 6
  year: 2019
  ident: 10513_CR76
  publication-title: Appl Microbiol Biotechnol
  doi: 10.1007/s00253-019-09645-x
– volume: 16
  start-page: e34
  issue: 4
  year: 2016
  ident: 10513_CR86
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(16)00070-0
– volume: 23
  start-page: 185
  issue: 4
  year: 2015
  ident: 10513_CR56
  publication-title: Trends Microbiol
  doi: 10.1016/j.tim.2015.01.006
SSID ssj0012866
Score 2.387091
SecondaryResourceType review_article
Snippet More than 100 years have passed since the discovery of Mycobacterium tuberculosis , in 1882, as the pathogen that causes tuberculosis (TB). However, globally,...
More than 100 years have passed since the discovery of Mycobacterium tuberculosis, in 1882, as the pathogen that causes tuberculosis (TB). However, globally,...
More than 100 years have passed since the discovery of Mycobacterium tuberculosis, in 1882, as the pathogen that causes tuberculosis (TB). However, globally,...
SourceID proquest
gale
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 4197
SubjectTerms Antibiotics
Antitubercular agents
Antitubercular Agents - pharmacology
Antitubercular Agents - therapeutic use
Bacterial infections
Bioinformatics
Biomedical and Life Sciences
Biotechnology
Care and treatment
Clinical Trials as Topic
Computational Biology
Development strategies
Drug development
Drug discovery
Drug resistance
Drug resistance in microorganisms
Drugs
Health aspects
Homeopathy
Humans
Infectious diseases
Life Sciences
Materia medica and therapeutics
Microbial Genetics and Genomics
Microbiology
Mini-Review
Multidrug resistance
multiple drug resistance
Mycobacterium tuberculosis
Mycobacterium tuberculosis - drug effects
pathogens
Patient compliance
phage therapy
Phages
Pharmaceutical industry
R&D
Research & development
research and development
Sustainable development
synthetic biology
Therapeutics
Tuberculosis
Tuberculosis - drug therapy
Tuberculosis - microbiology
Tuberculosis, Multidrug-Resistant - drug therapy
SummonAdditionalLinks – databaseName: SpringerLink Journals (ICM)
  dbid: U2A
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8QwEA6iCHoQ364voggeNLBNmjY5LqKooIK64C0kaSuCtmJ3D_57Z_rSFRU8zzRtJ5kXM_OFkANrIweprGfW-j4Ls1Ay57lmmUsgn4i0iqqb566uo_NhePkgH5qhsLLtdm9LkpWl7obd0D1jzbEPpkMGgoHhnZGYu8MpHvJBVzvgqq5QgmNksdSqGZX5eY0Jd_TdKH_xSt_KpJX3OVskC03YSAf1Pi-RqTRfJrP1RZLvy2T-C6zgCrkBy0VfP6coS1rkFAI92nWV0yKjL-8edLnCaoaV26asvKTYCv9IQeJP7qlAFOdVMjw7vT85Z83FCczLOBwxbpPUcssFePNMqlg7mdq-zQIVJ1KAeUsiIVwIJO10FHjQehvbwCXCQwbRd2KNTOdFnm4QCuINAp-JxHoVCtjFMFE6dVYkWFFM4x4JWvkZ36CK4-UWz6bDQ65kbkDmppK54T1y1D3zWmNq_Mm9j9tiEKwix26YRzsuS3Nxd2sGEQYkkDEB02HDlBXwem-b4QL4CcS3muDcnuAEbfKT5Hb3TaPNpeECcfnAb-gfyQJLkRAnR7JH9joyLowNbHlajHGJWCkdQ3D8Bw9OKQvM-HpkvT54nXwEhGIyFEA5bk_i5wf8LrzN_7FvkTmOylE1dG6T6dHbON2BoGvkdisd-wDsyB4F
  priority: 102
  providerName: Springer Nature
Title New perspectives on the treatment of mycobacterial infections using antibiotics
URI https://link.springer.com/article/10.1007/s00253-020-10513-2
https://www.ncbi.nlm.nih.gov/pubmed/32185432
https://www.proquest.com/docview/2396098769
https://www.proquest.com/docview/3195323165
https://www.proquest.com/docview/2378897575
https://www.proquest.com/docview/2439431182
Volume 104
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR1Nb9Mw1IJNSHBAML4KYzIIiQNYNHYcxyfUQssAMdCgUneybCeZJm1JIe1h_573EiddJ-gph_fiJM9-X3lfhLyyNnHgynpmrR-yuIglc55rVrgM_IlEp0kzee7bUXI4i7_M5Tz8cKtDWmUnExtBnVUe_5G_ExjvAWMkke8XvxlOjcLoahihcZPsYusyTOlS897hAtHbxipBRTIldRqKZprSOVT2GMEcgiCSkWB8QzFdF89X9NO1gGmjh6b3yN1gQNJRu-P3yY283CO32pGSl3vkzpUGgw_Id5BhdLGup6xpVVIw-WifX06rgl5ceuDqpmszrNylZ5U1xaT4Uwq0P3NnFfZzfkhm08mvD4csjFBgXqp4ybjNcsstF6DXC5kq7WRuh7aIUpVJAYIuS4RwMYC000nkgf-tspHLhAdfYujEI7JTVmX-hFDwX6PIFyKzPo0F7GecpTp3VmQYW8zVgEQd_YwP_cVxzMW56TsjNzQ3QHPT0NzwAXnT37Nou2tsxX6J22KwbUWJeTGndlXX5vPPYzNK0DQB3wmQXgekooLHexvKDOAjsNPVBub-Bibwld8Ed7tvAl_Xhgvs0AcaRP8TvD6kA_KiB-PCmMpW5tUKl1BpqhWYyVtwsF5ZoO83II_bg9fTR4BRJmMBkLfdSVy_wP-J93T7-z4jtzkyQ5PKuU92ln9W-XMwt5buoOGpA7I7Gn8cT_H66eTrBK7jydGPY4DO-Ogvo4EmyQ
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3ZbtNAcFRSIeABQbkCBRYE4gFWxLteHw8IFWiV0DagHlLflt21XVUCO-BEKD_FNzLjK00FeevzjDf27JyZC-CFMYHFUNZxY9yA-5mvuHUi5plNMJ4I4iioNs_tj4Phsf_5RJ2swZ-2F4bKKludWCnqpHD0H_lbSfkedEYC9X7yk9PWKMqutis0arbYTee_MWQr340-4f2-FGJn--jjkDdbBbhToT_lwiSpEUZINHWZisLYqtQMTOZFYaIkyn4SSGl9BMU2DjyHImFC49lEOnSvB1biuVdg3ZcYyvRg_cP2-OtBl7cQUZ0dRaPMQxVHTZtO1axH7gXlTAeo-pQnuVgyhRcNwjmLeCFFW1m-nVtws3FZ2VbNY7dhLc034Gq9xHK-ATfOjTS8A19Qa7LJooOzZEXO0MlkXUU7KzL2Y-5Qj1RzovHktiAsLxmV4Z8yvO0ze1bQBOm7cHwp5L0HvbzI0wfAMGL2PJfJxLjIl8hBfhLFqTUyoWxmGvbBa-mnXTPRnBZrfNfdLOaK5hppriuaa9GH190zk3qex0rs53QtmgZl5FSJc2pmZalHhwd6KyBnCKM1RHrVIGUF_rwzTWMDfgTN1lrC3FzCREl2y-D29nWjSUotJM0ERJsV_xO8EIs-POvAdDAVz-VpMaMjwiiKQ3TMV-BQh7SkaLMP92vG6-gj0Q1UvkTIm5YTFy_wf-I9XP2-T-Ha8Gh_T--NxruP4LogwagKSTehN_01Sx-jsze1TxoJY_DtsoX6L70HXr0
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQwcFSKQHBAUF4LBQwCcQCrGzuOkwNCFWXVpVAQUGlvxnaSqhIkC9kV2l_j65jJa7sV7K1nj51kPM_MC-CptZFDV9Zza_2Qh3mouPMi4blL0Z-IkjiqJ899OIz2j8J3EzXZgD9dLQylVXYysRbUaenpH_mOpHgPGiOR2snbtIhPe6PX05-cJkhRpLUbp9GQyEG2-I3uW_VqvId3_UyI0duvb_Z5O2GAe6XDGRc2zaywQqLay1WsE6cyO7R5EOtUSZQDaSSlC3EpcUkUeGQPq23gUunR1B46iedegIsa9xOP6Unv7KHYb-KkqJ65VkncFuzUZXtkaFD0dIhCEHdysaIUz6qGU7rxTLC21oGj63CtNV7ZbkNtN2AjK7bgUjPOcrEFV081N7wJH1F-sumylrNiZcHQ3GR9bjsrc_Zj4VGi1B2j8eQuNayoGCXkHzO89xN3UlIv6VtwdC7IvQ2bRVlkd4Gh7xwEPpep9XEokZbCNE4yZ2VKcc1MDyDo8Gd829ucRmx8N31X5hrnBnFuapwbMYAX_Z5p09ljLfQTuhZDLTMKIr5jO68qM_7y2exGZBah34ZAz1ugvMTHe9uWOOBHUJetFcjtFUjkab-63N2-aWVKZYSk7oCovZJ_Li8ZZACP-2U6mNLoiqyc0xE6jhONJvoaGKqVluR3DuBOQ3g9fiQahCqUuPKyo8TlC_wfeffWv-8juIysbN6PDw_uwxVBfFFnlG7D5uzXPHuAVt_MPazZi8G38-bnv4cYYY0
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=New+perspectives+on+the+treatment+of+mycobacterial+infections+using+antibiotics&rft.jtitle=Applied+microbiology+and+biotechnology&rft.au=He%2C+Yile&rft.au=Fan%2C+Aili&rft.au=Han%2C+Meng&rft.au=Zhang%2C+Yihan&rft.date=2020-05-01&rft.pub=Springer&rft.issn=0175-7598&rft.volume=104&rft.issue=10&rft.spage=4197&rft_id=info:doi/10.1007%2Fs00253-020-10513-2&rft.externalDBID=ISR&rft.externalDocID=A622405762
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0175-7598&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0175-7598&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0175-7598&client=summon